PFG Investments LLC Purchases 2,145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

PFG Investments LLC raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,674 shares of the biotechnology company’s stock after buying an additional 2,145 shares during the quarter. PFG Investments LLC’s holdings in Sarepta Therapeutics were worth $3,331,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SRPT. Wealth Enhancement Advisory Services LLC boosted its holdings in Sarepta Therapeutics by 100.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 2,504 shares during the last quarter. Hudson Capital Management LLC bought a new position in shares of Sarepta Therapeutics in the first quarter valued at about $220,000. Commonwealth Equity Services LLC boosted its holdings in shares of Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after buying an additional 418 shares during the period. Van ECK Associates Corp raised its holdings in Sarepta Therapeutics by 5.3% in the 1st quarter. Van ECK Associates Corp now owns 86,329 shares of the biotechnology company’s stock valued at $11,176,000 after acquiring an additional 4,374 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Sarepta Therapeutics by 111.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company’s stock worth $12,131,000 after acquiring an additional 47,895 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction dated Friday, August 16th. The stock was bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $0.88 during trading on Friday, hitting $131.14. 849,647 shares of the company were exchanged, compared to its average volume of 1,243,304. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a market capitalization of $12.40 billion, a P/E ratio of 1,192.18 and a beta of 0.82. The business’s 50 day moving average is $128.73 and its 200-day moving average is $132.43.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the previous year, the firm posted ($0.27) EPS. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Citigroup lowered their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 14th. Jefferies Financial Group began coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target on the stock. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, Barclays lowered their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.